Plain-English translation of NCT06519578 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing two different chemotherapy approaches for advanced liver cancer. Both methods deliver medication directly into the artery that feeds the liver—a technique called hepatic arterial infusion chemotherapy. The study will compare how well Raltitrexed with oxaliplatin works against a combination of 5-Fluorouracil, leucovorin, and oxaliplatin to see which is more effective and safer for patients.
Advanced liver cancer is difficult to treat with standard chemotherapy because most of the drug washes away before it can attack the tumor. This study exists to determine whether delivering the medication directly into the liver's blood supply—so it stays concentrated where the cancer is—can improve outcomes for patients with advanced disease.
You likely qualify if…
You likely don't qualify if…
You will be assigned to receive one of the two chemotherapy combinations, delivered through a catheter placed into the artery supplying your liver. You will receive treatment once every 3 weeks. The study will track how well the treatment works, monitor you for side effects through blood tests and imaging scans, and follow your health for an extended period to see how long the benefit lasts.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China